← Back to Clinical Trials
Recruiting NCT07608614

NCT07608614 Sleep and Performance

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07608614
Status Recruiting
Phase
Sponsor University of Washington
Condition Sleep
Study Type INTERVENTIONAL
Enrollment 16 participants
Start Date 2025-10-01
Primary Completion 2027-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 30 Years
Study Type INTERVENTIONAL
Interventions
Transcranial Electric StimulationSham Comparator

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 16 participants in total. It began in 2025-10-01 with a primary completion date of 2027-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This research is being done to apply new, contrast-free MRI (Magnetic Resonance Imaging) methods to understand the brain's waste clearance system (the "glymphatic" system) in younger adults. The Investigators hope the study will show how the different brain regions are involved in maintaining memories and how poor sleep affects these regions and our ability to remember. The Investigators will test whether the Wireless Interface Sensor Pod (WISP) improves brain function after poor sleep. The WISP is a headband that combines tracking brain waves and transcranial electrical stimulation (TES) to monitor and improve slow wave sleep and glymphatic clearance. IParticipants will be asked to: * Complete 4 in-person study visits (1 per week) over 4 weeks at the Diagnostic Imaging Sciences Center (DISC), located at the University of Washington Medical Center at Montlake, Seattle. Each visit will last 2 hours and includes a 1 hour MRI and 1 hour of cognitive testing. * Complete a daily journal about sleep, daily habits, etc. * The night before each of the four study visits, participants will sleep while wearing the WISP headband. * For two of these nights, participants will sleep only 3 hours prior to normal time of awakening. The WISP will deliver a small electrical current for one night and not for the other night, but participants will not know which. * For the other two nights, participants will follow a normal sleep schedule. The WISP will deliver a small electrical current for one night and not for the other night, but participants will not know which.

Eligibility Criteria

Inclusion Criteria: 1. Physically and psychologically healthy 2. Good habitual sleep between 6 and 10 hours in duration, as assessed by questionnaire and pre-study week sleep/wake diary 3. Regular bedtimes, habitually getting up between 05:00 and 09:00, as assessed by questionnaire and pre-study week sleep/wake diary Exclusion Criteria: * Subjects who have any type of non-MRI compatible bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.), because such devices may be displaced or malfunction. * Subjects who have any type of ferromagnetic bioimplant that could potentially be displaced. * Subjects who have cerebral aneurysm * Subjects who may have shrapnel imbedded in their bodies (such as from war wounds), metal workers and machinists (potential for metallic fragments in or near the eyes). * Minors (younger than 18 years) * Pregnant women ( Participants of childbearing potential will receive a urine pregnancy test. If the test is positive, the participant will be excluded) * Breastfeeding * Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher. * no clinical disorders and/or illnesses, no psychiatric illnesses), as assessed by history and questionnaires * no alcohol during study and no normal excessive alcohol consumption assessed by questionnaire * No history of drug or alcohol abuse in the past year and no history of methamphetamine abuse, as assessed by questionnaires. * Not a dependent smoker or vaper, and not morning dependent on tobacco, nicotine, or cannabis, as assessed by questionnaire. * No history of moderate to severe brain injury, as assessed by questionnaire * No anti-psychotic medication for ADHD/ADD, as assessed by questionnaire * No previous adverse reaction to sleep deprivation, as assessed by questionnaire * Not vision-impaired unless corrected back to normal. * Not hearing impaired unless corrected to normal, as assessed by questionnaire * Not pregnant, as assessed by history and questionnaire * No sleep or circadian disorder, as assessed by questionnaires * No use of melatonin within 1 week of study enrollment * No travel across more than one time zone within one month of entering the study and no crossing times zones during study participation, as assessed by questionnaire. * No shift work within three months of entering the study and no shift work during duration study participation, as assessed by questionnaire. * epilepsy

Contact & Investigator

Central Contact

Yeilim Cho, MD

✉ ycho7@uw.edu

📞 (206) 277-7207

Principal Investigator

Jeffrey Iliff, PhD

PRINCIPAL INVESTIGATOR

University of Washington

Frequently Asked Questions

Who can join the NCT07608614 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 30 Years, studying Sleep. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07608614 currently recruiting?

Yes, NCT07608614 is actively recruiting participants. Contact the research team at ycho7@uw.edu for enrollment information.

Where is the NCT07608614 trial being conducted?

This trial is being conducted at Seattle, United States.

Who is sponsoring the NCT07608614 clinical trial?

NCT07608614 is sponsored by University of Washington. The principal investigator is Jeffrey Iliff, PhD at University of Washington. The trial plans to enroll 16 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology